Benzofuran derivatives useful for treating hyper-proliferative disorders

A method of treating a hyper-proliferative disorder in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound of formula (I)

• wherein
• Ar1 is selected from benzodioxolyl, pyrrolidinyl, pyridyl or pyridyl N-oxide, each optionally mono-substituted with C(O)NH2, halo, (C1-C3)alkoxy, amino, hydroxy(C1-C3)alkyl, or (C1-C3)alkyl optionally substituted with aminocarbonyl or (C1-C3)alkylcarbonylamino,
• a five-membered aromatic heterocycle optionally substituted with 1 or 2 substituents each independently selected from (C1-C3)alkyl, C(O)H, C(O)(C1-C3)alkyl, and halo, and
• phenyl optionally substituted with 1 or 2 substituents each selected independently from OH, —OCF3, CF3, CN, halo, NO2, NR5R5, NHC(O)R6, NHS(O)2R5, NHS(O)2NR5R5, S(O)nR8, 1C(O)R10, C(O)NH(C1-C3)alkoxy-(C1-C3)alkyl, C(O )NH(C3-C6)cycloalkyl, pyrrolidinonyl, imidazolinyl, imidazolidinonyl, (C1—C3)alkoxy optionally substituted with 1 or 2 OH groups, and (C1-C3)alkyl optionally mono-substituted with CN, OH, NR5R5, NHC(O)R6, NHS(O)2(C1-C3) alkyl, C(O)NR5R5, oxazolidinonyl, imidazolidinonyl optionally mono-substituted with (C1-C3) alkyl, pyrrolidinonyl optionally mono-substituted with (C1-C3)alkyl, a five-membered N containing heterocycle optionally mono-substituted with (C1-C3)alkyl, piperazinyl optionally mono-substituted with (C1-C3)alkyl, pyridyl optionally mono-substituted with CF3 or (C1-C3) alkoxy, thienyl optionally mono-substituted with C(O)(C1-C3)alkyl, or pyrimidinyl optionally mono-substituted with NRC[(C1-C3)alkyl]2;
• Ar2 is selected from benzodioxolyl, phenyl optionally substituted with 1 or 2 substituents each selected independently from (C1-C3)alkyl, (C1-C3)alkoxy, OH, NO2, CN, halo, and CF3, and pyridyl mono-substituted with (C1-C3)alkyl or CF3;
• R1, R2, and R3 are hydrogen;
• R4 is selected from hydrogen, (C1-C3)alkyl, (C1-C3)alkoxy, CN, and C(O)NHR5, wherein (C1-C3)alkyl can optionally be substituted with halo, (C1-C3)alkoxy, hydroxyalkylamino, alkoxyalkylamino;
• R5 is selected from H, (C3-C6)cycloalkyl, and (C1-C3)alkyl optionally substituted with 1 or 2 OH groups or mono-substituted with (C1-C3)alkoxy, (C1-C3)alkylamino, S(O)2(C1-C3) alkyl, or C(O)R7;
• R6 is selected from H, (C3-C6)cycloalkyl, (C1-C3)alkoxy, (C2-C6)alkenyl, CHF2, CF3,NHR5, and (C1-C3)alkyl optionally substituted with one or more substituents selected from Cl and F, or optionally mono-substituted with NH2 or NHC(O)(C1-C3)alkyl;
• R7 is selected from (C1-C3)alkoxy, (C2-C6)alkenyl, CHF2, CF3, (C3-C6)cycloalkyl, NR7-1R7-1, and (C1-C3)alkyl optionally substituted with one or more substituents selected from Cl and F, or mono-substituted with NHC(O)(C1-C3)alkyl or NH2, wherein R7-1 is hydrogen or (C1-C3)alkyl;
• R8 is selected from (C1-C3)alkyl and NR9R9;
• R9 is selected from H and (C1-C3)alkyl optionally mono-substituted with (C1-C3)alkoxy, or aminocarbonyl, or substituted with 1 or 2 OH groups;
• R10 is selected from H, (C1-C3)alkoxy, NHR9, and (C1-C3)alkyl optionally mono-substituted with pyrrolidinyl, morpholinyl, pyridinyl, piperazinyl optionally substituted with (C1-C3)alkyl, or piperidinyl optionally substituted with (C1-C3)alkyl;
• n is 0, 1, or 2;
• or a pharmaceutically acceptable salt thereof.